Sinovac Biotech (SVA) Competitors

Sinovac Biotech logo
$6.47 0.00 (0.00%)
As of 11/16/2026

SVA vs. ABSI, NVAX, NUVB, TYRA, and ANAB

Should you buy Sinovac Biotech stock or one of its competitors? Sinovac Biotech's main competitors and comparable companies include Absci (ABSI), Novavax (NVAX), Nuvation Bio (NUVB), Tyra Biosciences (TYRA), and AnaptysBio (ANAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sinovac Biotech compare to Absci?

Absci (NASDAQ:ABSI) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Absci had 29 more articles in the media than Sinovac Biotech. MarketBeat recorded 29 mentions for Absci and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 1.79 beat Absci's score of 0.01 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Absci Neutral
Sinovac Biotech Very Positive

Sinovac Biotech has a net margin of 0.00% compared to Absci's net margin of -8,451.31%. Sinovac Biotech's return on equity of 0.00% beat Absci's return on equity.

Company Net Margins Return on Equity Return on Assets
Absci-8,451.31% -61.60% -55.30%
Sinovac Biotech N/A N/A N/A

Sinovac Biotech has higher revenue and earnings than Absci.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Absci$2.80M467.66-$115.18M-$0.79N/A
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A

Absci has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Absci currently has a consensus target price of $14.90, indicating a potential upside of 96.57%. Sinovac Biotech has a consensus target price of $1.00, indicating a potential downside of 84.54%. Given Absci's higher probable upside, analysts plainly believe Absci is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Absci
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.83
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

52.1% of Absci shares are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Sinovac Biotech beats Absci on 8 of the 14 factors compared between the two stocks.

How does Sinovac Biotech compare to Novavax?

Novavax (NASDAQ:NVAX) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Novavax has a beta of 2.65, suggesting that its share price is 165% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Sinovac Biotech has a net margin of 0.00% compared to Novavax's net margin of -18.64%. Sinovac Biotech's return on equity of 0.00% beat Novavax's return on equity.

Company Net Margins Return on Equity Return on Assets
Novavax-18.64% -14.82% -7.55%
Sinovac Biotech N/A N/A N/A

53.0% of Novavax shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Novavax has higher revenue and earnings than Sinovac Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$1.12B1.17$440.30M-$0.46N/A
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A

In the previous week, Novavax had 4 more articles in the media than Sinovac Biotech. MarketBeat recorded 4 mentions for Novavax and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 1.79 beat Novavax's score of 0.56 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Novavax Positive
Sinovac Biotech Very Positive

Novavax presently has a consensus target price of $13.60, suggesting a potential upside of 70.85%. Sinovac Biotech has a consensus target price of $1.00, suggesting a potential downside of 84.54%. Given Novavax's higher possible upside, research analysts plainly believe Novavax is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax
2 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Novavax and Sinovac Biotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Sinovac Biotech compare to Nuvation Bio?

Sinovac Biotech (NASDAQ:SVA) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Sinovac Biotech currently has a consensus target price of $1.00, suggesting a potential downside of 84.54%. Nuvation Bio has a consensus target price of $12.89, suggesting a potential upside of 229.39%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Nuvation Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67

Sinovac Biotech has higher revenue and earnings than Nuvation Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A
Nuvation Bio$62.90M21.96-$204.63M-$0.40N/A

In the previous week, Nuvation Bio had 5 more articles in the media than Sinovac Biotech. MarketBeat recorded 5 mentions for Nuvation Bio and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 1.79 beat Nuvation Bio's score of 0.12 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Sinovac Biotech Very Positive
Nuvation Bio Neutral

61.7% of Nuvation Bio shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sinovac Biotech has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market.

Sinovac Biotech has a net margin of 0.00% compared to Nuvation Bio's net margin of -67.38%. Sinovac Biotech's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Sinovac BiotechN/A N/A N/A
Nuvation Bio -67.38%-45.69%-18.54%

Summary

Sinovac Biotech and Nuvation Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Sinovac Biotech compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

84.1% of Tyra Biosciences shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tyra Biosciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Sinovac Biotech's return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Tyra BiosciencesN/A -40.12% -37.62%
Sinovac Biotech N/A N/A N/A

In the previous week, Tyra Biosciences had 22 more articles in the media than Sinovac Biotech. MarketBeat recorded 22 mentions for Tyra Biosciences and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 1.79 beat Tyra Biosciences' score of -0.20 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Tyra Biosciences Neutral
Sinovac Biotech Very Positive

Tyra Biosciences currently has a consensus price target of $47.40, suggesting a potential upside of 142.21%. Sinovac Biotech has a consensus price target of $1.00, suggesting a potential downside of 84.54%. Given Tyra Biosciences' higher probable upside, equities research analysts clearly believe Tyra Biosciences is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tyra Biosciences
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Sinovac Biotech has higher revenue and earnings than Tyra Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tyra BiosciencesN/AN/A-$119.95M-$2.64N/A
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A

Summary

Sinovac Biotech beats Tyra Biosciences on 8 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to AnaptysBio?

Sinovac Biotech (NASDAQ:SVA) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

AnaptysBio has a net margin of 96.30% compared to Sinovac Biotech's net margin of 0.00%. Sinovac Biotech's return on equity of 0.00% beat AnaptysBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Sinovac BiotechN/A N/A N/A
AnaptysBio 96.30%-17.54%-1.08%

Sinovac Biotech currently has a consensus price target of $1.00, suggesting a potential downside of 84.54%. AnaptysBio has a consensus price target of $75.67, suggesting a potential upside of 65.90%. Given AnaptysBio's higher possible upside, analysts plainly believe AnaptysBio is more favorable than Sinovac Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
AnaptysBio
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69

Sinovac Biotech has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

AnaptysBio has lower revenue, but higher earnings than Sinovac Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sinovac Biotech$386.01M1.67-$59.68MN/AN/A
AnaptysBio$234.60M5.78-$13.23M$4.969.20

In the previous week, AnaptysBio had 12 more articles in the media than Sinovac Biotech. MarketBeat recorded 12 mentions for AnaptysBio and 0 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 1.79 beat AnaptysBio's score of 0.79 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Sinovac Biotech Very Positive
AnaptysBio Positive

Summary

Sinovac Biotech and AnaptysBio tied by winning 6 of the 12 factors compared between the two stocks.

Get Sinovac Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SVA vs. The Competition

MetricSinovac BiotechBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$644.66M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.7134.3428.32
Price / Sales1.6715.788.495.70
Price / Cash11.8922.9521.0121.90
Price / Book0.074.184.453.72
Net Income-$59.68M-$24.15M$3.52B$393.10M
7 Day PerformanceN/A-7.81%-5.93%-5.77%
1 Month PerformanceN/A-5.99%-4.58%-7.14%
1 Year PerformanceN/A-8.09%-1.94%-7.46%

Sinovac Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SVA
Sinovac Biotech
1.3025 of 5 stars
$6.47
flat
$1.00
-84.5%
N/A$644.66M$386.01MN/A3,008
ABSI
Absci
3.0983 of 5 stars
$8.45
-7.5%
$15.00
+77.5%
+165.0%$1.45B$2.80MN/A140
NVAX
Novavax
1.9985 of 5 stars
$8.52
-2.7%
$12.33
+44.8%
+17.1%$1.41B$1.12BN/A749
NUVB
Nuvation Bio
2.8808 of 5 stars
$4.00
-1.6%
$12.89
+222.6%
-16.1%$1.40B$62.90MN/A310
TYRA
Tyra Biosciences
2.4427 of 5 stars
$20.02
+1.3%
$47.40
+136.8%
+23.1%$1.38BN/AN/A87

Related Companies and Tools


This page (NASDAQ:SVA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners